Neumora Therapeutics, Inc. (NMRA)

Neumora Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-243.79	-235.93	-130.9	-237.31	-99.27
Depreciation & Amortization	0.63	0.67	0.59	0.54	0.11
Asset Writedown & Restructuring Costs	-	63.9	13	157	69.86
Loss (Gain) From Sale of Investments	-5.72	-3.74	-0.71	-	-
Stock-Based Compensation	39.99	17.24	8.3	4.27	1.68
Other Operating Activities	3.31	3.48	1.77	1.04	3.99
Change in Accounts Payable	2.87	-0.58	-1.25	-0.76	-4.67
Change in Other Net Operating Assets	19.76	-8.32	-5.7	-0.2	1.55
Operating Cash Flow	-182.94	-163.28	-114.9	-75.42	-26.76
Capital Expenditures	-	-0.12	-0.51	-0.82	-1.3
Cash Acquisitions	-	-	-	-	2.81
Sale (Purchase) of Intangibles	-0.78	-4.59	-13	-	-
Investment in Securities	-69.78	69.09	-154.5	-	-
Other Investing Activities	-	-	-	-	-12.75
Investing Cash Flow	-70.56	64.39	-168.01	-0.82	-11.24
Long-Term Debt Issued	-	-	-	-	55.91
Net Debt Issued (Repaid)	-	-	-	-	55.91
Issuance of Common Stock	21.6	236.23	2.66	3.47	3.19
Repurchase of Common Stock	-	-0.49	-	-	-0
Other Financing Activities	-	-3.8	-0.92	-1.21	-0.9
Financing Cash Flow	21.6	231.94	115.74	293.51	230.1
Net Cash Flow	-231.89	133.05	-167.17	217.27	192.1
Free Cash Flow	-182.94	-163.4	-115.41	-76.24	-28.06
Free Cash Flow Per Share	-1.15	-2.51	-4.24	-3.48	-2.16
Cash Income Tax Paid	0.47	-	-	-	-
Levered Free Cash Flow	-100.7	-111.24	-93.02	-37.08	-
Unlevered Free Cash Flow	-100.7	-111.24	-93.02	-37.08	-
Change in Net Working Capital	-24.12	6.82	11.61	-9.12	-

Source: S&P Capital IQ. Standard template. Financial Sources.